Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia

Other Phase I/II or IIa trials are planned with this drug candidate In the context of the French new "anti-cancer plan" announcement, IPH 2101 was presented to government officials Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗